NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
| Event: | H.C. Wainwright 25th Annual Global Investment Conference |
| Date: | Presentation to be accessible on-demand, beginning |
| 7:00 AM EDT, Monday, September 11th, 2023 | |
| Format: | Virtual company presentation and 1-on-1 meetings |
| Registration: | https://journey.ct.events/view/9083a450-c597-41e2-8a02-2ffe070bef75 |
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
Irina Koffler
LifeSci Advisors, LLC
+1 646 970 4681
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.91 |
| Daily Change: | 0.11 14.19 |
| Daily Volume: | 30,471,781 |
| Market Cap: | US$94.480M |
January 23, 2025 January 22, 2025 January 10, 2025 January 08, 2025 December 17, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
